Jessie Hanrahan Sells 4,134 Shares of Solid Biosciences (NASDAQ:SLDB) Stock

Solid Biosciences Inc. (NASDAQ:SLDB) insider Jessie Hanrahan sold 4,134 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.82, for a total value of $24,059.88. Following the completion of the sale, the insider owned 74,318 shares of the company’s stock, valued at $432,530.76. This represents a 5.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jessie Hanrahan also recently made the following trade(s):

• On Wednesday, February 4th, Jessie Hanrahan sold 12,348 shares of Solid Biosciences stock. The stock was sold at an average price of $6.44, for a total value of $79,521.12.
• On Monday, February 2nd, Jessie Hanrahan sold 26,535 shares of Solid Biosciences stock. The stock was sold at an average price of $6.44, for a total value of $170,885.40.
• On Monday, February 2nd, Jessie Hanrahan sold 26,535 shares of Solid Biosciences stock. The shares were sold at an average price of $6.44, for a total value of $170,885.40.
• On Wednesday, December 3rd, Jessie Hanrahan sold 4,483 shares of Solid Biosciences stock. The shares were sold at an average price of $5.11, for a total transaction of $22,908.13.

Solid Biosciences Stock Performance

Shares of NASDAQ SLDB opened at $5.88 on Friday. Solid Biosciences Inc. has a 52-week low of $2.41 and a 52-week high of $7.37. The stock has a market cap of $458.11 million, a P/E ratio of -2.36 and a beta of 2.67. The firm has a 50 day moving average price of $5.95 and a 200 day moving average price of $5.68.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SLDB. AQR Capital Management LLC bought a new position in shares of Solid Biosciences during the first quarter worth about $418,000. Goldman Sachs Group Inc. boosted its position in Solid Biosciences by 32.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company’s stock worth $667,000 after acquiring an additional 43,910 shares during the last quarter. Woodline Partners LP bought a new position in shares of Solid Biosciences during the 1st quarter worth approximately $2,338,000. ProShare Advisors LLC acquired a new stake in shares of Solid Biosciences in the second quarter valued at approximately $80,000. Finally, Geode Capital Management LLC lifted its position in shares of Solid Biosciences by 184.5% in the second quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock worth $7,356,000 after purchasing an additional 979,294 shares in the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on SLDB. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. JPMorgan Chase & Co. decreased their target price on Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Chardan Capital reaffirmed a “buy” rating and set a $15.00 price target on shares of Solid Biosciences in a research report on Tuesday, November 4th. Barclays set a $9.00 price objective on Solid Biosciences and gave the company an “overweight” rating in a report on Tuesday, November 4th. Finally, Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a research note on Monday, February 9th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.70.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.